secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0000950170-25-017879
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics Q4 net loss $37.3M; cash at $1.9B; 50+ ATCs activated
-------------------------------------------------------------------------

- Q4 2024 net loss of $37.3M vs net income of $89.3M in Q4 2023.
- Cash, cash equivalents, and marketable securities of $1,903.8M, up from $1,695.7M a year earlier.
- Over 50 authorized treatment centers activated globally for CASGEVY; >50 patients have had cells collected.
- R&D expenses fell to $82.2M in Q4 2024 from $95.1M in Q4 2023.
- Pipeline catalysts in 2025: CTX112 updates mid-2025; CTX310/320 updates H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025017879/0000950170-25-017879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017025017879/crsp-20250211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-017879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer